BioSpace News Archive

SciSparc Ltd. announced the full exercise of 3,211,100 pre-funded warrants that were issued as part of a private placement financing for gross proceeds of $10 million, which closed on June 1, 2022.

Axsome Therapeutics, Inc. announced that the FDA has approved AUVELITY™ extended-release tablets for the treatment of major depressive disorder in adults.

IASO Biotherapeutics announced that the Center for Drug Evaluation of China’s National Medical Products Administration approved its investigational new drug application for the new extended indication of Neuromyelitis Optica Spectrum Disorder for a fully human BCMA chimeric antigen receptor autologous T cell Injection.

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2022 fourth quarter and full year on Wednesday, August 24, 2022, after the market closes.

Ginkgo Bioworks today announced the purchase of certain epidemiological data infrastructure assets from Baktus, Inc.

Intercept Pharmaceuticals, Inc. announced today that it has entered into privately negotiated agreements to repurchase $327.9 million of its secured convertible debt using a combination of cash and equity.

Kymera Therapeutics, Inc. has entered into a securities purchase agreement with certain existing and new accredited investors to issue and sell an aggregate of 2,769,228 shares of its common stock (“Common Stock”) at a price of $26.00 per share.

Palatin Technologies, Inc. today announced that it intends to effect a 1-for-25 reverse split of its issued and outstanding common stock (the “Reverse Stock Split”).

Catalyst Biosciences, Inc. today announced that JDS1, LLC, one of the Company’s stockholders, has dismissed its lawsuits against the Company.

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Lauren Sabella, Chief Operating Officer, will resign from the Company effective September 30, 2022.